Ignite Creation Date:
2024-05-05 @ 9:08 PM
Last Modification Date:
2024-10-26 @ 9:59 AM
Study NCT ID:
NCT00810693
Status:
COMPLETED
Last Update Posted:
2023-11-22
First Post:
2008-12-17
Brief Title:
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension PAH
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Randomized Double-blind Placebo-controlled Multi-centre Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 1 mg 15 mg 2 mg or 25 mg Tid in Patients With Symptomatic Pulmonary Arterial Hypertension PAH
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PATENT-1
Brief Summary:
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks in patients with symptomatic Pulmonary Arterial Hypertension PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-003482-68 | EUDRACT_NUMBER | None | None |